{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:05:27Z","timestamp":1789470327764,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.semarthrit.2026.153068","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:03:29Z","timestamp":1787587409000},"page":"153068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Performance of respiratory patient reported outcome instruments in systemic sclerosis associated interstitial lung disease trials: Are we falling at the first hurdle?"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-3358","authenticated-orcid":false,"given":"Matthew","family":"Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana J","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2364","authenticated-orcid":false,"given":"John D","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7349","authenticated-orcid":false,"given":"Shaney L","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.153068_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0002","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107659","article-title":"Patient and caregiver shared experiences of pulmonary fibrosis (PF): a systematic literature review","volume":"227","author":"Wells","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0005","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0006","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0007","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0008","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0009","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0011","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0014","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0015","doi-asserted-by":"crossref","DOI":"10.5662\/wjm.v15.i2.98066","article-title":"Voices that matter: The impact of patient-reported outcome measures on clinical decision-making","volume":"15","author":"Jeyaraman","year":"2025","journal-title":"World J Methodol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0016","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) \u2014 report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0017","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.semarthrit.2021.08.001","article-title":"Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process","volume":"51","author":"Roofeh","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 106","key":"10.1016\/j.semarthrit.2026.153068_bib0018","first-page":"184","article-title":"Patient participation in patient-reported outcome instrument development in systemic sclerosis","volume":"35","author":"Pauling","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1590\/bjpt-rbf.2014.0143","article-title":"The consensus-based standards for the selection of health measurement instruments (COSMIN) and how to select an outcome measurement instrument","volume":"20","author":"Mokkink","year":"2016","journal-title":"Braz J Phys Ther"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0020","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0021","unstructured":"US Department of Health and Human Services. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. (2009). 1\u201339 p."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0022","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11136-009-9528-5","article-title":"Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments","volume":"18","author":"Terwee","year":"2009","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0023","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0025","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0026","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/1756-185X.14177","article-title":"Effects of supervised exercise program and home exercise program in patients with systemic sclerosis: a randomized controlled trial","volume":"24","author":"Yakut","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0027","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0028","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/rheumatology\/keae156","article-title":"Efficacy of methylprednisolone in very early systemic sclerosis: results of the \u201cHit Hard and Early\u201d randomized controlled trial","volume":"64","author":"Kersten","year":"2025","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0029","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1093\/rheumatology\/keaf062","article-title":"Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study","volume":"64","author":"Chung","year":"2025","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0030","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s10067-025-07433-9","article-title":"BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trial","volume":"44","author":"Chen","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0031","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3899\/jrheum.161040","article-title":"Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"45","author":"Hsu","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/rheumatology\/kel221","article-title":"Validity of the Saint George\u2019s Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis","volume":"46","author":"Beretta","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0035","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-024-06950-3","article-title":"Divergent perspectives: exploring the relationships between St. George\u2019s Respiratory Questionnaire and outcome measures in systemic sclerosis\u2013associated interstitial lung disease","volume":"43","author":"Basaran","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0036","first-page":"235","article-title":"Evaluation of the functional parameters in scleroderma cases with pulmonary involvement","volume":"58","author":"Celebi S\u00f6zener","year":"2010","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0037","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5152\/ArchRheumatol.2025.11105","article-title":"Association of health-related quality of life with functional and radiological outcomes in patients with rheumatoid arthritis\u2013associated interstitial lung disease, systemic sclerosis\u2013associated interstitial lung disease, and idiopathic pulmonary fibrosis","volume":"40","author":"Sahino\u011flu","year":"2025","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0038","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/23971983211013979","article-title":"Quality of life in SSc-ILD patients: understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France","volume":"7","author":"Allanore","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0039","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/resp.13084","article-title":"Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases","volume":"22","author":"Cheng","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5152\/ThoracResPract.2024.23135","article-title":"The validity and reliability of the Turkish version of modified medical research council dyspnea scale in systemic sclerosis patients with interstitial lung disease","volume":"25","author":"Gur Kabul","year":"2024","journal-title":"Thorac. Res. Pract."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/diagnostics16010158","article-title":"Systemic sclerosis-associated ILD: insights and limitations of ScleroID","volume":"16","author":"Ni\u021b\u0103","year":"2026","journal-title":"Diagnostics"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0042","article-title":"PO:33:191 | Evaluation of the living with pulmonary fibrosis questionnaire in patients with systemic sclerosis associated interstitial lung disease: monocentric results","volume":"77","author":"Barison","year":"2025","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0043","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/rheumatology\/keu456","article-title":"Reliability, validity and responsiveness to change of the Saint George\u2019s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis","volume":"54","author":"Wallace","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0044","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0046","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/23971983251318827","article-title":"Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters","volume":"10","author":"Ponniah","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0047","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/art.20787","article-title":"Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the scleroderma lung study","volume":"52","author":"Khanna","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 119","key":"10.1016\/j.semarthrit.2026.153068_bib0048","first-page":"49","article-title":"Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease","volume":"37","author":"Fisher","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0049","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/art.22580","article-title":"Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study","volume":"56","author":"Khanna","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0050","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0051","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0052","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0053","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King\u2019s brief interstitial lung disease (K-BILD) health status questionnaire","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0054","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the living with idiopathic pulmonary fibrosis questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0055","doi-asserted-by":"crossref","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","article-title":"The living with pulmonary fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0056","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George\u2019s respiratory questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0057","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jval.2010.11.009","article-title":"Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD)","volume":"14","author":"Yount","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0058","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jval.2010.06.001","article-title":"Development of a conceptual framework and calibrated item banks to measure patient-reported dyspnea severity and related functional limitations","volume":"14","author":"Choi","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0059","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1524-4733.2009.00547.x","article-title":"A conceptual model of the experience of dyspnea and functional limitations in chronic obstructive pulmonary disease","volume":"12","author":"Victorson","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0060","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0061","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/COPD-120030829","article-title":"Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD","volume":"1","author":"Mahler","year":"2004","journal-title":"COPD: J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0062","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0063","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","article-title":"Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire","volume":"81","author":"Becker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0064","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/23971983251334162","article-title":"Cognitive debriefing of the scleroderma health assessment questionnaire in diffuse cutaneous systemic sclerosis","volume":"10","author":"Khanna","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0065","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0066","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1056\/NEJMe068095","article-title":"Cyclophosphamide for Scleroderma Lung Disease","volume":"354","author":"Martinez","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0067","article-title":"ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF","volume":"7","author":"Durheim","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0068","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"Herzog","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0069","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/23971983221083882","article-title":"Clinical characteristics associated with small airways disease in systemic sclerosis","volume":"7","author":"Varma","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0071","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0072","series-title":"Global strategy for prevention, diagnosis and management of COPD","year":"2025"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0073","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/acr.25056","article-title":"Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis","volume":"75","author":"Ross","year":"2023","journal-title":"Arthritis Care Res (Hob.)"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0074","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/2397198320904178","article-title":"Patient-reported outcome measures in systemic sclerosis\u2013related interstitial lung disease for clinical practice and clinical trials","volume":"5","author":"Saketkoo","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0076","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0091-2022","article-title":"Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties","volume":"31","author":"Lemmers","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.semarthrit.2026.153068_bib0077","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/thx.2009.118521","article-title":"Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12","volume":"65","author":"Yorke","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0078","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","article-title":"Measuring respiratory symptoms of COPD: performance of the EXACT- respiratory symptoms tool (E-RS) in three clinical trials","volume":"15","author":"Leidy","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0079","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1378\/chest.113.3.619","article-title":"Validation of a New Dyspnea Measure","volume":"113","author":"Eakin","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","volume":"85","author":"Antoniou","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0081","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.2.5147.257","article-title":"The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population","volume":"2","author":"Fletcher","year":"1959","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2026.153068_bib0082","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:26:38Z","timestamp":1789467998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":82,"alternative-id":["S0049017226001587"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153068","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of respiratory patient reported outcome instruments in systemic sclerosis associated interstitial lung disease trials: Are we falling at the first hurdle?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153068"}}